Project Grant P01CA275740
Award Date
8/8/24
Completion Date
7/31/29
Dollars Obligated
$2.7M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA Program 93.396 - Cancer Biology Research) totaling $2,397,277 will support research at the Sanford Burnham Prebys Medical Discovery Institute to investigate the role of metabolic stress and hypernutrition in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC). The research will focus on understanding how interactions between cellular signaling pathways (NRF2, ATF6) and mitochondrial...
This federal Project Grant award of $599,299 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Illinois to investigate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its connection to non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The research aims to further validate the importance of HK2 in liver fibrosis development and its impact on NASH-induced HCC, a leading cause of...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
The National Cancer Institute (NCI) awarded a $232,515 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Loyola University of Chicago's Health Sciences Campus. The grant supports research to define the molecular mechanisms and identify biomarkers for focal adhesion kinase (FAK)-driven hepatocellular carcinoma (HCC), a deadly form of liver cancer. The key objectives are to: 1) determine how FAK promotes expression of the tumor-promoting protein CTGF in HCC, 2) evaluate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment (TIME) of liver cancer or hepatocellular carcinoma (HCC) during HIV infection. The 5-year project aims to: 1) Characterize how TAPDC reprogram the HCC TIME in HCC-HIV mouse models and human samples; 2) Define how TAPDC modulate...
This Project Grant award, identified as K08CA286847, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The $171,135 award, effective March 10, 2025 through February 28, 2030, supports the "SMALL LIVER CANCER: DEVELOPMENT OF A MULTI-LEVEL INTERVENTION TO IMPROVE ACCESS TO CURE (LIVER:CURE)" project at Weill Medical College of Cornell University. The project aims to develop the principal investigator's capacity...
This Project Grant award, valued at $593,042.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award will support research by The Leland Stanford Junior University (Stanford University) to investigate the role of the complement pathway in macrophage reprogramming and the progression of hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatohepatitis (MASH). The key research objectives are to:...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Tulane University is focused on investigating the role of the long non-coding RNA CRNDE in hepatocellular carcinoma (HCC) and its impact on tumor-infiltrating lymphocytes (TILs). The total award amount is $468,139, with a project period from March 15, 2025 to February 28, 2030. The key objectives of this research project are to elucidate the molecular mechanisms by which HCC-derived CRNDE...
This $104,096 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research to identify genetic dependencies specific to subtypes of hepatocellular carcinoma (HCC). The project will utilize a hybrid in vivo and in silico approach to determine whether HCC genetic dependencies demonstrate subtype specificity based on pathomolecular features. Specific aims include: 1) using in vivo loss-of-function screening to assess...